Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading v

U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira so

Barclays assumed coverage on shares of Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) in a r

Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia,

Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Under

Intellia Therapeutics (NASDAQ:NTLA) released second-quarter financial results and hosted an earnings

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) and Intellia Therapeutics (NASDAQ: NTLA - Get

Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditar

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its fi

Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) shares passed below its fifty day movin

Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conferen

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency

Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outp

Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral a

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA)

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicin

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutio

FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 Positions lonvo-z to be the w

Public Employees Retirement System of Ohio acquired a new position in Intellia Therapeutics, Inc. (N

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a l

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolution

$75 million funded upfront with an additional $325 million tied to milestones, providing strategic f

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a l

Bank of New York Mellon Corp purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ: NTLA) in

Cathie Wood's ARK sold 40,392 Shopify shares after a 25% August rally. Here's what ARKK and

Ark Invest was a buyer of tech stocks down as much as 53% from their recent all-time highs.

Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outp

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation,

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration reven

Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pha

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a

Top Wall Street analysts updated their ratings on top companies. For full list of changes, including

U.S. stock futures up, Nasdaq 100 gains 100 points. Robinhood shares fall 10.7% after reporting lowe

Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan

Top analysts upgraded RPM, Dow, Intellia, Sempra, & Target stocks. See ratings & targets. Po

Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raise

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil